Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C or RAD51D Mutations or RAD51-foci Low Test: RADIOLA TRIAL

NCT05340413 is registered in ClinicalTrials.gov with SOLTI Breast Cancer Research Group as lead sponsor.

NCT NCT05340413
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05340413 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predicting Olaparib Sensitivity in Patients With Unresectable Locally Advanced/Metastatic HER2-negative Breast Cancer With BRCA1, BRCA2, PALB2, RAD51C or RAD51D Mutations or RAD51-foci Low Test: RADIOLA TRIAL
Lead sponsor
SOLTI Breast Cancer Research Group
Phase
Phase 2
Overall status
Completed
Start date
March 25, 2022
Completion date
February 3, 2025
Enrollment
65 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

her2-negative breast cancer, metastatic breast cancer, triple negative breast cancer